Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Adjuvant Belzutifan-Pembrolizumab Significantly Boosts DFS in Kidney Cancer



(MedPage Today) — SAN FRANCISCO — The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival (DFS) in patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy versus…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments